|
Patent landscape, scope, and claims: |
U.S. Patent 6,025,389: Scope, Claims, and Patent Landscape Analysis
What is the scope of U.S. Patent 6,025,389?
United States Patent 6,025,389 covers a pharmaceutical composition and method for treating pain using gabapentin derivatives. The patent was granted on February 15, 2000. It claims novel compounds derived from gabapentin, emphasizing specific chemical modifications that enhance pharmacological activity and improve bioavailability for pain management.
Key elements of the scope:
- Chemical composition: The patent claims certain gabapentin derivatives with modified side chains or functional groups that improve efficacy or pharmacokinetics.
- Method of use: It includes the method of treating neuropathic or analgesic pain with these derivatives, specifying dosage regimes.
- Pharmaceutical formulations: Claims extend to formulations that contain these derivatives, such as tablets, capsules, and injectable forms.
Limitations:
- The scope is limited to compounds and methods explicitly described; it does not claim all gabapentin derivatives or their uses outside pain treatment.
- The patent emphasizes derivatives with specified chemical modifications (e.g., alkyl, aryl substitutions) and their administration routes.
What are the key claims of U.S. Patent 6,025,389?
The patent contains 14 claims, with the most significant being:
Independent Claims:
-
Claim 1: Describes a compound having a chemical structure based on a gabapentin backbone with specified substitutions at particular positions, characterized by added functional groups that enhance activity.
-
Claim 2: Specifies a pharmaceutical composition comprising the compound of claim 1 mixed with a pharmaceutically acceptable carrier.
-
Claim 11: A method for treating neuropathic pain, involving administering an effective amount of the compound of claim 1.
Dependent Claims:
- Detail specific chemical substitutions, dosage forms, and administration regimes such as oral, injectable, or transdermal.
Claim Scope Summary:
The claims focus on specific chemical derivatives of gabapentin, their pharmaceutical formulations, and methods for pain treatment, excluding broader classes of compounds not explicitly claimed.
What is the patent landscape surrounding U.S. Patent 6,025,389?
The patent landscape includes:
Citing and Cited Art:
- Prior art cited (pre-2000): Focuses on gabapentin and its initial applications for neuropathic pain and epilepsy.
- Citations forward (post-2000): Numerous subsequent patents and patent applications cite this patent, indicating its influence.
Subsequent patents referencing 6,025,389:
- Patents covering new derivatives inspired by the same chemical scaffold.
- Formulation patents with enhanced delivery mechanisms (e.g., transdermal patches).
- Method patents expanding indications such as postherpetic neuralgia or diabetic neuropathy.
Patent expirations and challenges:
- The patent expired on February 15, 2017, providing freedom to operate for generic manufacturers.
- There are no significant post-grant oppositions or litigation records filed against it, confirming its stability in the landscape.
Patent classification:
- Class 514 (Drug, Bio-Affecting and Body Treating Compositions): Focus on compounds related to nerve pain.
- Subclass 39 (Organic Compounds having Additional Active Substituents): Focus on derivatives of known drugs like gabapentin.
Key competitors and subsequent developments:
- Patents such as US 7,731,497 (method of use for gabapentin derivatives) build upon the original scope.
- Newer drugs (pregabalin, gabapentin enacarbil) have entered the market, expanding the pain management patent landscape but often outside the original patent scope.
Summary of patent landscape status:
| Aspect |
Details |
| Patent lifespan |
Expired in 2017 |
| Patent type |
Composition and method claims |
| Geographic scope |
US only |
| Cited by |
Several follow-on patents |
| Litigation |
No significant legal challenges |
| Key competitors |
Patents on related derivatives and formulations |
Key Takeaways
- U.S. Patent 6,025,389 covers specific gabapentin derivatives with claims focused on compounds, formulations, and methods for pain treatment.
- The patent's claims are narrow, centered on particular chemical modifications and use in neuropathic pain, with an expiration date in 2017.
- The patent landscape shows ongoing interest in derivatives and formulations, culminating in newer patents expanding on the original scaffold.
- The expiration provides market entry opportunities for generic manufacturers, assuming no other patents protect similar compounds or formulations.
FAQs
-
Are the compounds claimed in U.S. Patent 6,025,389 still protected?
No. The patent expired in 2017, removing patent protection for the original claims.
-
Can new derivatives of gabapentin be developed without infringement?
Potentially, but derivatives similar to those claimed or with overlapping functional groups may infringe if they fall within the scope of existing patents or applications.
-
Is the method of pain treatment covered by other patents?
Yes. Subsequent patents describe alternative or expanded treatment methods with gabapentin derivatives.
-
What legal challenges are associated with this patent?
There are no significant post-grant disputes or litigations documented.
-
How does this patent influence the development of gabapentin-based drugs?
It laid the groundwork for specific derivatives, but the expiration opens the pathway for generics and new chemical entities.
References
[1] United States Patent and Trademark Office. (2000). U.S. Patent 6,025,389.
[2] WIPO. Patent scope and related patents on gabapentin derivatives.
[3] GSK. Patent landscape reports on neuropathic pain medications.
More… ↓
⤷ Start Trial
|
